T. Rowe Price (TROW) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Cellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.